Document Detail

Pharmacologic therapies after myocardial infarction.
MedLine Citation:
PMID:  8900339     Owner:  NLM     Status:  MEDLINE    
Despite the availability and use of effective methods for limiting infarct size with thrombolytic agents and primary angioplasty, patients experiencing a myocardial infarction (MI) are at increased risk for a second cardiac event in the post-MI period (e.g., reinfarction, heart failure, and sudden death). For this reason, postinfarction risk management is crucial. An extensive data base has firmly established the efficacy of beta blockers in reducing cardiovascular risk following acute MI. The full advantages of angiotensin-converting enzyme (ACE) inhibitors have only recently begun to emerge as the result of a growing understanding of the mechanisms of adverse outcomes following MI. The importance of lipid-lowering agents, in particular the "statins," should be considered in all post-MI patients, especially since recent studies have conclusively shown improved survival and reduced rates of MI and coronary artery bypass surgery in this population with this therapy. Aspirin is now considered a standard part of the early management of the acute infarct patient as well as for secondary prevention in post-MI patients. At present, chronic anticoagulation with warfarin should be reserved for selected patients. The nondihydropyridine calcium antagonists diltiazem and verapamil can be considered for post-MI use only in patients in whom beta blockers are contraindicated and who have preserved systolic function and/or those without clinical heart failure. In contrast, the dihydropyridine calcium antagonists, particularly nifedipine, have no role in secondary prevention. Although long-term benefits are minimal, nitrates continue to be useful in post-MI patients with residual ischemia (angina or silent ischemia), heart failure (systolic or diastolic), or postinfarction hypertension. Antiarrhythmic agents, except amiodarone, are relatively contraindicated in post-MI patients. Recent data show that vitamin E reduces the rate of nonfatal MI. Its role in cardiovascular death and overall mortality remains to be clarified. Despite their demonstrated value, agents used in secondary prevention generally appear to be underutilized. In addition, when pharmacologic therapies are administered for secondary prevention, they are often prescribed at lower doses than those tested and proved in trials. A greater appreciation for the efficacy and safety profiles of these agents could lead to more widespread use and more pronounced reductions in morbidity and mortality among post-MI patients.
E Rapaport; M Gheorghiade
Related Documents :
15550779 - Effects of high- and low-dose amiodarone on mortality, left ventricular remodeling, and...
15764619 - Timi, pursuit, and grace risk scores: sustained prognostic value and interaction with r...
20223059 - Spectroscopic diagnosis of myocardial infarction and heart failure by fourier transform...
2115819 - Beneficial effect of intravenous nitroglycerin in patients with non-q myocardial infarc...
15329749 - High-sensitivity c-reactive protein is predictive of medium-term cardiac outcome in hig...
23782929 - Fatal ischemic stroke complicating acute multifocal placoid pigment epitheliopathy: his...
1927949 - Periodicity of global ventricular activation of sinus beats in patients with coronary a...
7828619 - Reverse redistribution of thallium-201 represents a low-risk finding in thrombolysed pa...
8809529 - Potential cardioembolic sources in an elderly population without stroke. a transthoraci...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American journal of medicine     Volume:  101     ISSN:  0002-9343     ISO Abbreviation:  Am. J. Med.     Publication Date:  1996 Oct 
Date Detail:
Created Date:  1996-12-05     Completed Date:  1996-12-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  4A61S-69S; discussion 4A69S-70S     Citation Subset:  AIM; IM    
San Francisco General Hospital, California 19440-0846, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Anti-Arrhythmia Agents / therapeutic use
Anticoagulants / therapeutic use
Antilipemic Agents / therapeutic use
Antioxidants / therapeutic use
Aspirin / therapeutic use
Calcium Channel Blockers / therapeutic use
Clinical Trials as Topic
Myocardial Infarction / drug therapy*,  mortality
Nitrates / therapeutic use
Platelet Aggregation Inhibitors / therapeutic use
Treatment Outcome
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Anti-Arrhythmia Agents; 0/Anticoagulants; 0/Antilipemic Agents; 0/Antioxidants; 0/Calcium Channel Blockers; 0/Nitrates; 0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Estrogen replacement therapy.
Next Document:  Cost effectiveness of risk reduction: the managed care perspective.